Linagliptin Stada

Linagliptin, the active ingredient in Linagliptin Stada, is a dipeptidyl peptidase-4 (DPP-4) inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to improve glycaemic control when used with diet and exercise.

GNH USA supplies Linagliptin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is a DPP‑4 inhibitor used in the treatment of type 2 diabetes mellitus, acting on the incretin pathway to improve glucose regulation.

- Type 2 diabetes mellitus: improves blood glucose control when combined with diet and exercise. - Inadequate control with metformin alone: provides additional glycaemic lowering as an adjunct therapy. - Combination therapy: can be used with other antidiabetic agents such as sulfonylureas or insulin to achieve target HbA1c levels.

Linagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Headache: transient mild to moderate headache. - Upper respiratory infection: cough, sore throat, or congestion. - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhoea.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain possibly radiating to the back. - Severe allergic reactions: rash, angio‑edema, or anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice. - Bullous pemphigoid: blistering skin disorder. - Severe hypoglycaemia: when combined with insulin or sulfonylureas.

Before initiating Linagliptin, consider patient‑specific factors and monitor for potential risks.

- Renal impairment: dose adjustment is not required, but monitor renal function regularly. - Hepatic impairment: use with caution in patients with moderate to severe liver disease. - Cardiovascular disease: assess cardiovascular status as part of overall diabetes management. - Elderly patients: monitor for adverse events, as they may be more susceptible. - Pregnancy and breastfeeding: safety not established; avoid unless benefits outweigh risks. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Linagliptin may interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase linagliptin exposure and risk of adverse effects. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce linagliptin plasma concentrations, diminishing efficacy.

Moderate Interactions (Monitor Closely): - Insulin or sulfonylureas: concurrent use can increase the risk of hypoglycaemia. - Diuretics (e.g., thiazides): may affect blood glucose control. - Antihypertensive agents: monitor blood pressure as glycaemic changes can influence cardiovascular status.